Clinical trial
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated…
NCT00056160 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00056160 |
|---|---|
| Title | CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma |
| Official title | A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | CC-5013, Dexamethasone |
| Enrollment | 353 |
| Start date | Jan 1, 2003 |
| Primary completion | Nov 1, 2005 |
| Completion | Oct 1, 2008 |
| First posted | Mar 7, 2003 |
| Last update posted | Oct 19, 2017 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: